Grifols, S.A. Stock Price, News & Analysis (NASDAQ:GRFS)

$23.17 -0.03 (-0.13 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$23.20
Today's Range$22.86 - $23.23
52-Week Range$14.33 - $24.20
Volume259,521 shs
Average Volume635,530 shs
Market Capitalization$6.09 billion
P/E Ratio21.56
Dividend Yield1.19%
Beta1.06

About Grifols, S.A. (NASDAQ:GRFS)

Grifols, S.A. logoGrifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.


Industry, Sector and Symbol:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:GRFS
  • CUSIP: N/A
  • Web: www.grifols.com
Debt:
  • Debt-to-Equity Ratio: 1.69%
  • Current Ratio: 3.17%
  • Quick Ratio: 1.39%
Price-To-Earnings:
  • Trailing P/E Ratio: 21.56
  • Forward P/E Ratio: 19.97
  • P/E Growth: 1.7
Sales & Book Value:
  • Annual Sales: $4.48 billion
  • Price / Sales: 3.53
  • Cash Flow: $1.33 per share
  • Price / Cash: 17.41
  • Book Value: $6.04 per share
  • Price / Book: 3.84
Dividend:
  • Annual Dividend: $0.28
  • Dividend Yield: 1.2%
Profitability:
  • Net Income: $603.60 million
  • Net Margins: 13.16%
  • Return on Equity: 18.08%
  • Return on Assets: 6.22%
Misc:
  • Employees: 14,877
  • Outstanding Shares: 682,820,000
 

Frequently Asked Questions for Grifols, S.A. (NASDAQ:GRFS)

What is Grifols, S.A.'s stock symbol?

Grifols, S.A. trades on the NASDAQ under the ticker symbol "GRFS."

How often does Grifols, S.A. pay dividends? What is the dividend yield for Grifols, S.A.?

Grifols, S.A. declared a semiannual dividend on Friday, May 26th. Stockholders of record on Thursday, June 1st will be given a dividend of $0.122 per share on Thursday, June 8th. This represents a dividend yield of 1.54%. The ex-dividend date is Tuesday, May 30th. View Grifols, S.A.'s Dividend History.

When did Grifols, S.A.'s stock split? How did Grifols, S.A.'s stock split work?

Grifols, S.A. shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols, S.A. stock prior to the split would have 200 shares after the split.

Who are some of Grifols, S.A.'s key competitors?

Who owns Grifols, S.A. stock?

Grifols, S.A.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Harding Loevner LP (13.12%), AKO Capital LLP (1.68%), Artisan Partners Limited Partnership (1.55%), Bank of New York Mellon Corp (0.91%), Pictet Asset Management Ltd. (0.32%) and Vaughan Nelson Investment Management L.P. (0.21%). View Institutional Ownership Trends for Grifols, S.A..

Who sold Grifols, S.A. stock? Who is selling Grifols, S.A. stock?

Grifols, S.A.'s stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Pictet Asset Management Ltd., AKO Capital LLP, Gladstone Capital Management LLP, Rock Point Advisors LLC, Oppenheimer Asset Management Inc., Beck Mack & Oliver LLC and Santa Barbara Asset Management LLC. View Insider Buying and Selling for Grifols, S.A..

Who bought Grifols, S.A. stock? Who is buying Grifols, S.A. stock?

Grifols, S.A.'s stock was purchased by a variety of institutional investors in the last quarter, including Harding Loevner LP, Westpac Banking Corp, GABELLI & Co INVESTMENT ADVISERS INC., First Trust Advisors LP, Citadel Advisors LLC, Gabelli Funds LLC, Ameriprise Financial Inc. and Van ECK Associates Corp. View Insider Buying and Selling for Grifols, S.A..

How do I buy Grifols, S.A. stock?

Shares of Grifols, S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Grifols, S.A.'s stock price today?

One share of Grifols, S.A. stock can currently be purchased for approximately $23.17.

How big of a company is Grifols, S.A.?

Grifols, S.A. has a market capitalization of $6.09 billion and generates $4.48 billion in revenue each year. Grifols, S.A. employs 14,877 workers across the globe.

How can I contact Grifols, S.A.?

Grifols, S.A.'s mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for Grifols, S.A. (NASDAQ GRFS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about Grifols, S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Grifols, S.A. (NASDAQ:GRFS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Grifols, S.A. (NASDAQ:GRFS)

Price Target History for Grifols, S.A. (NASDAQ:GRFS)

Analysts' Ratings History for Grifols, S.A. (NASDAQ:GRFS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017Citigroup Inc.Initiated CoverageBuy -> BuyN/AView Rating Details
7/4/2017Bank of America CorporationReiterated RatingBuyMediumView Rating Details
6/30/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralLowView Rating Details
3/30/2017J P Morgan Chase & CoUpgradeNeutral -> OverweightHighView Rating Details
6/6/2016Morgan StanleyReiterated RatingSellN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuyN/AView Rating Details
2/9/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History for Grifols, S.A. (NASDAQ:GRFS)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Grifols, S.A. (NASDAQ:GRFS)
2017 EPS Consensus Estimate: $1.13
2018 EPS Consensus Estimate: $1.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.26$0.26$0.26
Q2 20171$0.28$0.28$0.28
Q3 20171$0.28$0.28$0.28
Q4 20171$0.31$0.31$0.31
Q1 20181$0.29$0.29$0.29
Q2 20181$0.33$0.33$0.33
Q3 20181$0.31$0.31$0.31
Q4 20181$0.34$0.34$0.34
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Grifols, S.A. (NASDAQ:GRFS)

Most Recent Dividend:6/8/2017
Annual Dividend:$0.28
Dividend Yield:1.21%
Payout Ratio:24.14% (Based on This Year's Estimates)
21.54% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Grifols, S.A. (NASDAQ:GRFS)

Dividend History by Quarter for Grifols, S.A. (NASDAQ GRFS)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/26/2017semiannual$0.121.54%5/30/20176/1/20176/8/2017
11/22/2016$0.1512/5/201612/7/201612/7/2016
5/31/2016$0.116/2/20166/6/20166/6/2016
12/1/2015$0.3012/10/201512/14/201512/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Grifols, S.A. (NASDAQ GRFS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Grifols, S.A. (NASDAQ GRFS)

Source:
DateHeadline
Grifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from AnalystsGrifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 21 at 3:52 AM
ETFs with exposure to Grifols SA : November 16, 2017ETFs with exposure to Grifols SA : November 16, 2017
finance.yahoo.com - November 16 at 2:52 PM
$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter
www.americanbankingnews.com - November 7 at 5:40 PM
William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)
www.americanbankingnews.com - November 6 at 5:24 AM
Visit To Grifols Headquarters During Tumultuous Time In Catalonia - Seeking AlphaVisit To Grifols' Headquarters During Tumultuous Time In Catalonia - Seeking Alpha
seekingalpha.com - November 3 at 9:09 PM
ETFs with exposure to Grifols SA : November 2, 2017ETFs with exposure to Grifols SA : November 2, 2017
finance.yahoo.com - November 2 at 10:32 PM
Stocks Showing Rising Market Leadership: Grifols Earns 83 RS RatingStocks Showing Rising Market Leadership: Grifols Earns 83 RS Rating
finance.yahoo.com - October 31 at 8:39 PM
Grifols, S.A. (GRFS) Given Consensus Rating of "Hold" by BrokeragesGrifols, S.A. (GRFS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 27 at 3:28 AM
Grifols, (GRFS) vs. ContraFect Corporation (CFRX) Head to Head ComparisonGrifols, (GRFS) vs. ContraFect Corporation (CFRX) Head to Head Comparison
www.americanbankingnews.com - October 24 at 2:14 PM
ETFs with exposure to Grifols SA : October 23, 2017ETFs with exposure to Grifols SA : October 23, 2017
finance.yahoo.com - October 23 at 6:55 PM
Cubist Pharmaceuticals (CBST) & Grifols, (GRFS) Critical ReviewCubist Pharmaceuticals (CBST) & Grifols, (GRFS) Critical Review
www.americanbankingnews.com - October 22 at 6:22 AM
ContraFect Corporation (CFRX) & Grifols, (GRFS) Head to Head ContrastContraFect Corporation (CFRX) & Grifols, (GRFS) Head to Head Contrast
www.americanbankingnews.com - October 19 at 9:07 AM
ETFs with exposure to Grifols SA : October 10, 2017ETFs with exposure to Grifols SA : October 10, 2017
finance.yahoo.com - October 10 at 4:53 PM
Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 9 at 7:22 PM
Grifols, (GRFS) versus Its Peers Financial ReviewGrifols, (GRFS) versus Its Peers Financial Review
www.americanbankingnews.com - October 9 at 4:12 PM
FACTBOX-Companies with big business operations in CataloniaFACTBOX-Companies with big business operations in Catalonia
www.cnbc.com - October 7 at 6:03 AM
Grifols, S.A. (GRFS) Given Consensus Recommendation of "Hold" by AnalystsGrifols, S.A. (GRFS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 2 at 12:44 AM
Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cylinder)?Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cylinder)?
seekingalpha.com - September 29 at 4:34 PM
Grifols, (GRFS) vs. Its Peers Head-To-Head AnalysisGrifols, (GRFS) vs. Its Peers Head-To-Head Analysis
www.americanbankingnews.com - September 28 at 6:16 PM
Grifols, (GRFS) versus Its Rivals Critical ComparisonGrifols, (GRFS) versus Its Rivals Critical Comparison
www.americanbankingnews.com - September 27 at 2:06 AM
Cubist Pharmaceuticals (CBST) and Grifols, (GRFS) Critical ContrastCubist Pharmaceuticals (CBST) and Grifols, (GRFS) Critical Contrast
www.americanbankingnews.com - September 25 at 6:32 AM
Head to Head Survey: Idenix Pharmaceuticals (IDIX) & Grifols, (GRFS)Head to Head Survey: Idenix Pharmaceuticals (IDIX) & Grifols, (GRFS)
www.americanbankingnews.com - September 23 at 12:40 PM
Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?
seekingalpha.com - September 22 at 6:51 PM
Should Value Investors Consider Grifols (GRFS) Stock Now? - NasdaqShould Value Investors Consider Grifols (GRFS) Stock Now? - Nasdaq
www.nasdaq.com - September 22 at 1:50 PM
Financial Comparison: Grifols, (GRFS) versus The CompetitionFinancial Comparison: Grifols, (GRFS) versus The Competition
www.americanbankingnews.com - September 22 at 2:20 AM
Should Value Investors Consider Grifols (GRFS) Stock Now?Should Value Investors Consider Grifols (GRFS) Stock Now?
finance.yahoo.com - September 20 at 4:18 PM
Head-To-Head Contrast: Grifols, (GRFS) & Its PeersHead-To-Head Contrast: Grifols, (GRFS) & Its Peers
www.americanbankingnews.com - September 16 at 8:24 PM
Financial Survey: Grifols, (GRFS) and Dendreon (DNDN)Financial Survey: Grifols, (GRFS) and Dendreon (DNDN)
www.americanbankingnews.com - September 15 at 10:21 AM
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
finance.yahoo.com - September 14 at 3:13 AM
Grifols, S.A. (GRFS) Given Average Recommendation of "Hold" by BrokeragesGrifols, S.A. (GRFS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 7 at 12:30 AM
Comparing Humanigen (KBIO) & Grifols, (GRFS)Comparing Humanigen (KBIO) & Grifols, (GRFS)
www.americanbankingnews.com - September 5 at 8:46 PM
Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS - PR Newswire (press release)Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS - PR Newswire (press release)
www.prnewswire.com - September 1 at 7:36 PM
Grifols Is a Leader in High-Demand PlasmaGrifols Is a Leader in High-Demand Plasma
finance.yahoo.com - August 29 at 7:45 PM
Stocks Flashing Renewed Technical Strength: GrifolsStocks Flashing Renewed Technical Strength: Grifols
finance.yahoo.com - August 28 at 11:54 PM
Head to Head Contrast: Onyx Pharmaceuticals (ONXX) & Grifols SA, Barcelona (GRFS)Head to Head Contrast: Onyx Pharmaceuticals (ONXX) & Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - August 18 at 12:22 AM
Analyzing Durata Therapeutics (DRTX) and Grifols, (GRFS)Analyzing Durata Therapeutics (DRTX) and Grifols, (GRFS)
www.americanbankingnews.com - August 17 at 8:48 AM
XOMA Corporation (XOMA) vs. Grifols, (NASDAQ:GRFS) Head-To-Head ComparisonXOMA Corporation (XOMA) vs. Grifols, (NASDAQ:GRFS) Head-To-Head Comparison
www.americanbankingnews.com - August 13 at 12:10 AM
Trio of companies redraws map of East Bay drug manufacturingTrio of companies redraws map of East Bay drug manufacturing
www.bizjournals.com - August 3 at 4:06 PM
Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols Procleix Babesia Assay Under an Investigational New Drug ProtocolSelect American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol
finance.yahoo.com - August 1 at 7:45 PM
3 Things In Biotech You Should Learn Today: July 31, 20173 Things In Biotech You Should Learn Today: July 31, 2017
seekingalpha.com - July 31 at 6:48 PM
European ADRs Move Lower in Friday Trading - NasdaqEuropean ADRs Move Lower in Friday Trading - Nasdaq
www.nasdaq.com - July 28 at 9:52 PM
Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of "Hold" from AnalystsGrifols, S.A. (NASDAQ:GRFS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 19 at 12:16 AM
Interesting GRFS Put And Call Options For February 2018 - Nasdaq ... - NasdaqInteresting GRFS Put And Call Options For February 2018 - Nasdaq ... - Nasdaq
www.nasdaq.com - June 21 at 7:11 PM
Should Value Investors Consider Grifols (GRFS) Stock Right Now? - NasdaqShould Value Investors Consider Grifols (GRFS) Stock Right Now? - Nasdaq
www.nasdaq.com - June 16 at 6:16 PM
Should You Get Rid of USANA Health Sciences (USNA) Now?Should You Get Rid of USANA Health Sciences (USNA) Now?
www.zacks.com - March 6 at 8:58 AM
Interesting GRFS Put And Call Options For August 2017 - NasdaqInteresting GRFS Put And Call Options For August 2017 - Nasdaq
www.nasdaq.com - December 21 at 6:24 PM
Interesting GRFS Put And Call Options For August 2017Interesting GRFS Put And Call Options For August 2017
www.nasdaq.com - December 20 at 10:28 PM
Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85BHologic Agrees to Sell Blood Screening Business to Grifols for $1.85B
www.thestreet.com - December 14 at 11:15 PM
Hologic to sell stake in blood screening unit for $1.85 blnHologic to sell stake in blood screening unit for $1.85 bln
www.marketwatch.com - December 14 at 6:13 PM
Bullish Two Hundred Day Moving Average Cross - GRFSBullish Two Hundred Day Moving Average Cross - GRFS
www.nasdaq.com - November 10 at 11:01 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Grifols, S.A. (NASDAQ GRFS) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.